A new study by SWOG found that publicly funded cancer trials have saved over 3.34 million years of life, with a estimated cost of $125 per life year gained. The study analyzed data from 193 Phase III randomized trials and estimated the cumulative life years gained from each trial.
At ASCO 2017, SWOG investigators reported trials involving more than 10 cancer types and presented results on treatment-resistant metastatic colorectal cancer, breast cancer chemotherapies, high-risk prostate cancer, and the benefits of public funding for cancer research. The group's research has led to the approval of 14 cancer drugs,...
A Phase III clinical trial has shown that an immediate infusion of gemcitabine after bladder cancer tumor removal significantly reduces the risk of cancer recurrence. The study found a 34% reduction in recurrence risk, with no additional side effects compared to a saline infusion.
A study published in JAMA Oncology analyzes 18 years of data on Oregon's Death with Dignity Act, revealing that 64% of patients who used the law ingested the medication and died. The majority of users were older white men with college education, and cancer was the underlying terminal illness for 77% of cases.
Research from the SWOG study shows that nearly one in four patients treated with Gleevec will survive 10 years, highlighting the importance of banked biospecimens to drive new scientific findings. The study also found significant survival rates for patients with specific KIT mutations.
The DART trial is a national immunotherapy clinical trial testing leading-edge treatments for rare cancers. Patients will receive ipilimumab and nivolumab combination therapy to fight cancer, with the goal of shrinking tumors and evaluating side effects.
A new study reveals significantly better outcomes for patients with metastatic colorectal cancer when combining vemurafenib with standard treatments. The three-drug combination improved progression-free survival rates and tumor response rates compared to traditional therapies.
A major clinical trial has found that adding bortezomib to a standard two-drug regimen significantly prolongs the time before multiple myeloma cancer returns, giving patients about another year of remission. The study also shows that patients who receive this combination therapy live an average of six years after initial treatment.
Researchers found that vitamin E and selenium supplements did not prevent colorectal adenomas in a large-scale study. The findings suggest that these antioxidants have no evidence of preventing cancer.
A new study by SWOG found that duloxetine can significantly reduce joint pain in postmenopausal women with early stage breast cancer. The randomized trial tested the effectiveness of duloxetine against aromatase inhibitors, a common treatment for breast cancer, and showed rapid relief from pain.
High-risk acute myeloid leukemia (AML) patients can live longer with quicker identification and transplantation. Researchers found that rapidly identifying genetic mutations and matching donors increased two-year survival rates from 22% to 45%. The streamlined approach could establish a new standard of care for these patients.
The SWOG and The Hope Foundation's efforts are paying off, with 13 NCTN trials now open to veterans at participating medical centers. Veterans like Jerry Valentino have successfully enrolled in trials, responding well to cutting-edge treatments.
A SWOG study found widespread detection bias in prostate cancer biopsies, affecting younger, healthier men and those with family history or elevated PSA levels. Biases led to inconsistent results on risk factors, highlighting the need for rigorous data analysis and caution against assumptions.
SWOG investigators report on clinical trials for lung, prostate, breast, and other cancers, including Lung-MAP precision medicine trial. Trial results also highlight the reliability of CT scan tumor measurements for evaluating new drug effectiveness.
A clinical trial found that using PET imaging to guide chemotherapy significantly increases remission rates and reduces toxic side effects in advanced Hodgkin lymphoma patients. The study showed a promising approach to tailor treatment to individual patients, leading to a potential new standard of care.
A new study by SWOG found that negative cancer trials have a significant impact on cancer research, despite initial skepticism. The study analyzed 94 randomized Phase III cancer trials and found that the scientific impact of negative trials was similar to that of positive trials over time.
The Lung Cancer Master Protocol (Lung-MAP) trial is a groundbreaking collaboration that uses genomic profiling to match patients with promising new treatments. With the addition of nivolumab, an FDA-approved immunotherapy, the trial offers innovative therapies for advanced stage squamous cell lung cancer.
A SWOG trial shows that adding bortezomib to lenalidomide and dexamethasone therapy in early treatment improves remission time and life expectancy for myeloma patients by about a year, compared to the standard two-drug regime.